Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Institution Directory

Clinical trials at Huntsman Cancer Institute (University of Utah)

Sites in Salt Lake City, UT

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 10:44 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
1143
Shown on this page
12
Current sort
Recently updated
Campus scope
Huntsman Cancer Institute (University of Utah), Salt Lake City, UT
Additional filters apply within this campus.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this campus

These controls apply only within Huntsman Cancer Institute (University of Utah), Salt Lake City, UT. Default order is Recently updated. Add condition, therapy, sponsor, or recruitment status to narrow this page further.

Reset campus filters
Clear filters
Showing 25–36 of 1,143 matching trials with a site at Huntsman Cancer Institute (University of Utah), Salt Lake City, UT.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Recruiting Phase 3 Interventional

Study to Evaluate the Safety and Efficacy of Larsucosterol in Participants With Alcohol-associated Hepatitis (AH)

NCT07428538
Status at this site: Not yet recruiting
View directory record Official record
Conditions
Hepatitis
Interventions
Larsucosterol, Placebo
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
92
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 65 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 17, 2026, 10:44 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional Results available

Pembrolizumab With or Without Anetumab Ravtansine in Treating Patients With Mesothelin-Positive Pleural Mesothelioma

NCT03126630
Site status not listed — check the official record
View directory record Official record
Conditions
Pleural Malignant Mesothelioma
Interventions
Anetumab Ravtansine, Laboratory Biomarker Analysis, Pembrolizumab, Pharmacological Study
Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
32
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 23 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 17, 2026, 10:44 AM EDT
Recruiting Phase 1Phase 2 Interventional

First-in-Human Study of DS-3939a in Participants With Advanced Solid Tumors

NCT05875168
Status at this site: Recruiting
View directory record Official record
Conditions
Advanced Solid Tumor, Metastatic Solid Tumor
Interventions
DS-3939a
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
590 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
12
States / cities
Sarasota, Florida • Locust Grove, Georgia • Westwood, Kansas + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 17, 2026, 10:44 AM EDT
Recruiting Phase 2 Interventional

APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation

NCT04858334
Status at this site: Recruiting
View directory record Official record
Conditions
Pancreatic Acinar Cell Carcinoma, Pancreatic Adenosquamous Carcinoma, Pancreatic Squamous Cell Carcinoma, Resectable Pancreatic Acinar Cell Carcinoma, Resectable Pancreatic Adenocarcinoma, Resectable Pancreatic Adenosquamous Carcinoma, Resectable Pancreatic Carcinoma
Interventions
Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Olaparib, Placebo Administration
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
453
States / cities
Anchorage, Alaska • Fairbanks, Alaska • Kingman, Arizona + 305 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 17, 2026, 10:44 AM EDT
Recruiting Phase 1 Interventional

A Study of DS-1103a Combination Therapy in Participants With Advanced Solid Tumors

NCT05765851
Status at this site: Recruiting
View directory record Official record
Conditions
Advanced Solid Tumor
Interventions
DS-1103a, T-DXd
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
4
States / cities
Sarasota, Florida • Providence, Rhode Island • Salt Lake City, Utah + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 17, 2026, 10:44 AM EDT
Recruiting Phase 2 Interventional

A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer

NCT07659782
Status at this site: Recruiting
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
VS-7375
Drug
Lead sponsor
Verastem, Inc.
Industry
Eligibility
18 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
17
States / cities
Scottsdale, Arizona • Los Angeles, California • Tamarac, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 17, 2026, 10:44 AM EDT
Active, not recruiting Phase 3 Interventional

Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen

NCT07087054
Site status not listed — check the official record
View directory record Official record
Conditions
Carcinoid Syndrome, Carcinoid, Carcinoid Tumor, Carcinoid Tumor of Ileum, Carcinoid Tumor of Cecum, Carcinoid Tumor of Liver, Carcinoid Tumor of Pancreas, Carcinoid Syndrome Diarrhea, Carcinoid Intestine Tumor
Interventions
Paltusotine, Placebo
Drug
Lead sponsor
Crinetics Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
141 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
17
States / cities
Gilbert, Arizona • Newport Beach, California • New Haven, Connecticut + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 17, 2026, 10:44 AM EDT
Recruiting Not applicable Interventional

Accuro XV Ultrasound Imaging System for BoneEnhance and Fracture Detection Algorithms

NCT07853768
Status at this site: Recruiting
View directory record Official record
Conditions
Fracture Arm, Fracture Leg, Wrist Injury, Ankle Injury
Interventions
Accuro XV Ultrasound Imaging System
Device
Lead sponsor
Rivanna Medical, Inc.
Industry
Eligibility
5 Years and older
Enrollment
25,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
10
States / cities
San Francisco, California • Denver, Colorado • New Haven, Connecticut + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 17, 2026, 10:44 AM EDT
Recruiting Phase 2Phase 3 Interventional

RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy

NCT06154252
Status at this site: Recruiting
View directory record Official record
Conditions
Idiopathic Inflammatory Myopathy, Dermatomyositis, Anti-Synthetase Syndrome, Immune-Mediated Necrotizing Myopathy, Juvenile Dermatomyositis, Juvenile Polymyositis, Juvenile Idiopathic Inflammatory Myopathy (JIIM), Juvenile Myositis
Interventions
CABA-201 following preconditioning with fludarabine and cyclophosphamide
Biological
Lead sponsor
Cabaletta Bio
Industry
Eligibility
6 Years to 75 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
31
States / cities
Orange, California • San Francisco, California • Aurora, Colorado + 22 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 17, 2026, 10:44 AM EDT
Recruiting Phase 3 Interventional

Efficacy and Safety of 4F-PCC (4-Factor Prothrombin Complex Concentrate) in Adult Patients Undergoing Complex Cardiovascular Surgery With Cardiopulmonary Bypass (CPB)

NCT07094087
Status at this site: Not yet recruiting
View directory record Official record
Conditions
Complex Cardiovascular Surgery With Cardiopulmonary Bypass
Interventions
BE1116, FFP
Biological
Lead sponsor
CSL Behring
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
16
States / cities
Los Angeles, California • Atlanta, Georgia • Chicago, Illinois + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 17, 2026, 10:44 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Clinical Study of MK-4208/TERN-701 in Participants With Chronic Myeloid Leukemia (CML) (MK-4208-003/Tern701-1012/CARDINAL)

NCT06163430
Status at this site: Recruiting
View directory record Official record
Conditions
Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Chronic Myeloid Leukemia, Chronic Phase, Chronic Myeloid Leukemia
Interventions
MK-4208
Drug
Lead sponsor
Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years and older
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
18
States / cities
Birmingham, Alabama • Gilbert, Arizona • Orange, California + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 17, 2026, 10:44 AM EDT
Not yet recruiting Phase 3 Interventional

Cilostazol for Prevention of Recurrent Stroke Trial

NCT07174414
Site status not listed — check the official record
View directory record Official record
Conditions
Stroke Recurrence, Myocardial Infarction, Vascular Death, Ischemic Stroke, TIA (Transient Ischemic Attack), Stroke (CVA) or Transient Ischemic Attack, Recurrent Stroke
Interventions
Cilostazol 100 mg Tablets, Placebo
Drug
Lead sponsor
Stanford University
Other
Eligibility
40 Years and older
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
46
States / cities
Birmingham, Alabama • Mobile, Alabama • Chandler, Arizona + 37 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 17, 2026, 10:44 AM EDT

About this Huntsman Cancer Institute (University of Utah) institution page

What this page lists
ClinicalTrials.gov records that list Huntsman Cancer Institute (University of Utah) in Salt Lake City, UT as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status
A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Related: all institution pages, browse by condition, or browse by U.S. city.